# BTK
One study reported BTK mutations in approximately 7% of FL and 11% of transformed FL cases.<sup>1</sup> Another showed these mutations were more common, and typically co-occur in tumours with BCL2 translocations. Despite the known role of certain BTK mutations in acquired resistance to BTK inhibitors, these mutations were found in BTK inhibitor-naïve patients.<sup>2</sup> These mutations often occur in treatment-naive patients and lead to inactivation of the BTK protein through destabilization or by altering key residues involved in enzymatic activity.<sup>1</sup> The mutation pattern in DLBCL and FL implies the preferential accumulation of *inactivating mutations*. No notable hot spots have been described in this gene in the context of the cancers listed below. 

## Relevance tier by entity

|Entity|Tier|Description               |
|:------:|:----:|--------------------------|
|![DLBCL](images/icons/DLBCL_tier1.png) |1   |high-confidence DLBCL gene|
|![FL](images/icons/FL_tier1.png)    |1   |high-confidence FL gene   |

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source        |frequency (%)|
|:------:|:--------------:|:-------------:|
|DLBCL |GAMBL genomes |6.88         |
|DLBCL |Schmitz cohort|3.40         |
|DLBCL |Reddy cohort  |3.10         |
|DLBCL |Chapuy cohort |2.14         |
|FL    |GAMBL genomes |6.93         |

## Mutation pattern and selective pressure estimates

|Entity|aSHM|Significant selection|dN/dS (missense)|dN/dS (nonsense)|
|:------:|:----:|:---------------------:|:----------------:|:----------------:|
|BL    |No  |No                   | 0.964          | 8.202          |
|DLBCL |No  |Yes                  |18.082          |28.027          |
|FL    |No  |Yes                  |39.808          |35.548          |



View coding variants in ProteinPaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/BTK_protein.html)  or [hg38](https://morinlab.github.io/LLMPP/GAMBL/BTK_protein_hg38.html)

![image](images/proteinpaint/BTK_NM_000061.svg)

View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/BTK.html)  or [hg38](https://morinlab.github.io/LLMPP/GAMBL/BTK_hg38.html)

![image](images/proteinpaint/BTK.svg)

## References
1. *Hu N, Wang F, Sun T, Xu Z, Zhang J, Bernard D, Xu S, Wang S, Kaminski M, Devata S, Phillips T, Malek SN. Follicular Lymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation. Clin Cancer Res. 2021 Apr 15;27(8):2301-2313. doi: 10.1158/1078-0432.CCR-20-3741. Epub 2021 Jan 8. PMID: 33419778; PMCID: PMC8046715.*
2. *Schejbel L, Breinholt MF, Gang AO, Nielsen TH, Pedersen LM, Høgdall E, Nørgaard P. Inactivating BTK mutations in large B-cell lymphoma in a real-world cohort: Strong correlation with BCL2 translocation. EJHaem. 2022 Jun 24;3(3):936-939. doi: 10.1002/jha2.489. PMID: 36051027; PMCID: PMC9421985.*
## BTK Expression
![image](images/gene_expression/BTK_by_pathology.svg)
<!-- ORIGIN: albuquerqueEnhancingKnowledgeDiscovery2017a -->
<!-- FL: krysiakRecurrentSomaticMutations2017b -->
<!-- DLBCL: albuquerqueEnhancingKnowledgeDiscovery2017a -->
